There's no inconsistency with holding while being a little...

There's no inconsistency with holding while being a little sceptical, so please don't use the spurious retort again gekkowolf. I'm "Doing My Own Research" and looking for independent credible sources to help understand the osl panco data a bit more, as I would do with any biotech.

As you seem so certain of things, here are a couple of questions:
1. What's OSL's response when a Professor of Oncology asks a company representative: Does your panco trial confirm your device provided efficacy benefit over and above the results we already get with current chemotherapy and/or does it show it is better (more effective) than standard radiotherapy in head to head trial? If not, why should I use it?

2. What's OSL's response to the head of a reimbursement agency (let's say N.I.C.E. in UK) when asked: Does your panco trial confirm your device provided efficacy benefit over and above current chemotherapy and/or does it show it is better (more effective) than standard radiotherapy in a head to head trial? If not, why should we pay a premium for it?